Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect

NCT02830594 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02830594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02830594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2016
Completion date
January 16, 2024
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastric squamous cell carcinoma, gastroesophageal junction adenocarcinoma, metastatic malignant neoplasm in the stomach, stage iv esophageal adenocarcinoma ajcc v7, stage iv esophageal squamous cell carcinoma ajcc v7